![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
08/7/2020 16:48 | They aren’t ..... | ![]() john09 | |
08/7/2020 16:44 | Why would you want to buy the ADR's on Nasdaq, John09, when AMYT shares are very much cheaper on AIM.? ATB PAPILLON | ![]() ultrasharp | |
08/7/2020 16:42 | It’s now £1.80 equivalent, very volatile stocks on nasdaq, But how to buy? | ![]() john09 | |
08/7/2020 16:38 | Doesn’t look like i can buy ADS in USA on my app | ![]() john09 | |
08/7/2020 16:34 | What’s the code on Nasdaq. Can’t find them on my broker app | ![]() john09 | |
08/7/2020 16:25 | It sure does ab321. Either AMYT is being undervalued on AIM, or it's being overvalued on Nasdaq!! No doubt we'll find out soon enough and the AIM share price will rise up towards the Nasdaq sp, or the Nasdaq share price will drop towards the AIM share price Hopefully the former!! ATB papillon | ![]() ultrasharp | |
08/7/2020 16:18 | I wonder how the share price on the NASDAQ will impact on the LSE listing? Too difficult for an old thickie like me! I hear tell it will be positive but have no idea how the mechanics of it work. | ![]() bazworth | |
08/7/2020 16:02 | 5:1 equals GBP of approx £2:46 | ![]() alphabravo321 | |
08/7/2020 16:01 | Don't forget ADR's are not 1:1. | ![]() waterloo01 | |
08/7/2020 16:00 | Latest Nasdaq price $15:45 | ![]() alphabravo321 | |
08/7/2020 14:16 | Just 9 seconds between those 2 x 250k trades ab321 (value 2 x £500k). The trade timed first was reported before the trade timed 9 seconds later. They can't both be buys because the AMYT share price would have risen. I reckon they are a transfer between investment funds and priced at the quoted offer price. So I reckon one was a sell and the other was a buy. ATB PAPILLON | ![]() papillon | |
08/7/2020 14:12 | Amryt Pharma PLC AMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL | digadee | |
08/7/2020 14:07 | What are half million buts, ab321? :-) | ![]() papillon | |
08/7/2020 13:29 | I spoke too soon, two half million buts just gone through | ![]() alphabravo321 | |
08/7/2020 13:17 | It does seem a bit quiet...! | ![]() alphabravo321 | |
08/7/2020 13:08 | Have we debuted on NASDAQ yet? Maybe it's not today. I think the company would RNS it (on the day at least), so if it's today, we should hear something. Well, some big buys late yesterday and a £50k buy today. | ![]() nick rubens | |
08/7/2020 11:14 | ultra many thanks - is amyt then well placed to compete and prosper under nasdaq | ![]() ali47fish | |
08/7/2020 10:06 | Obviously just comparing them, ali47fish. Seems sensible as they are both developing treatments for rare skin conditions and both are, uniquely, developing gene based treatments for EB. They are potential competitors. ATB PAPILLON | ![]() ultrasharp | |
08/7/2020 08:53 | NASDAQ TRADE HALT AMYT.O REASON NOT AVAILABLE AT 04:00 AM Something is happening. It all seems very low key for such an important event. | baloo99 | |
08/7/2020 08:42 | has kb any relation to amyt or are you simply comparing them papillon | ![]() ali47fish | |
08/7/2020 08:07 | Perhaps it will appear later as NASDAQ opens? | ![]() bazworth | |
08/7/2020 07:49 | Surprised there is no RNS with the significance of today | ![]() alphabravo321 | |
08/7/2020 00:19 | Some corrections to my last post. Krystal Biotech's lead product for EB should have just entered phase III by now and it has around US$300m of cash on the balance sheet (so no debt). The Mkt Cap is circa US840m and it has around US$300m of cash having just raised US$125m in a placing. That makes AMYT's cash balance seem puny by comparison. However AMYT should post revenue of around US$150m in 2020 and Krystal Biotech is forecasting big losses for the next few years. I reckon my £4 share price target for AMYT pre the release of the AP101 phase III results could be too optimistic. I wouldn't like to predict a target share price for AMYT. It all depends on investor perceptions, both here and in New York, on Nasdaq. A £4 share price would give a Mkt Cap of just over £600 (Krystal Biotech's is currently equivalent to circa £660m). Of course AMYT has debt and KB has around US$300m of cash. However AMYT has 2 revenue generating drugs and possibly a third very soon. It also has that American fast track voucher that could be worth around US$100m if AP101 proves to be successful and the voucher is sold. | ![]() papillon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions